CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer

Patients with metastatic bladder cancer (mBC) treated with cisplatin-based chemotherapy have a limited median survival of only around 14 months [1]. Despite over 30 years of basic and clinical research, until recently no therapeutic options beyond cisplatin-based therapy had entered clinical routine...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Qi, Sathe, Anuja, Black, Peter C., Goebell, Peter J., Kamat, Ashish M., Schmitz-Draeger, Bernd, Nawroth, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409046/
https://www.ncbi.nlm.nih.gov/pubmed/28516152
http://dx.doi.org/10.3233/BLC-170105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409046/
https://www.ncbi.nlm.nih.gov/pubmed/28516152
http://dx.doi.org/10.3233/BLC-170105

Ejemplares similares